Furthermore, from the 245 HLA-I cancer-associated antigens common to both conditions, many were represented by more peptides following IFNγ treatment (Figure 3B) (A similar trend was observed across the total common source antigen pool, Supplementary Figure 5C). This evidence concerns the gene IFNG and cancer.